Clinical Trial Update: An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy

View source ↗

Summary

This clinical trial update describes an observational study of erlotinib as second-line therapy in locally advanced or metastatic non-small cell lung cancer aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Status: COMPLETED | Results posted: 2015-12-28